Current Medical Research and Opinion

State of Wisconsin to Provide Access to Prescription Digital Therapeutics to Help Local Communities Fight Against Addiction Crisis

Retrieved on: 
Thursday, November 3, 2022
Biotechnology, General Health, FDA, Health, Pharmaceutical, Health, FDA, Population, Pharmacoeconomics, Speech disorder, Policy by press release, DOI, BA, PDT, Substance abuse, Treatment, Buprenorphine, Comparison, Journal, Reading, Current Medical Research and Opinion, Substance use disorder, Language isolate, Wisconsin Department of Health Services, Pear, Williams–Campbell syndrome, Postgraduate Medicine, Safety, SUD, ClinicoEconomics and Outcomes Research, OUD, MBA, Cognitive behavioral therapy, Doctor of Philosophy, Insomnia, PEAR, Policy, Digital, Hospital Practice, Journal of Medical Economics, Digital therapeutics, Initiation, DHS, Smartphone, Randomized controlled trial, Therapy, Suicidal ideation, Reset, Risk, Opioid use disorder, MD, Pharmaceutical industry, Birth control, Hospital, Mobile phone, Medical device, Health insurance, Patient, Nasdaq

Eligible patients will be prescribed and treated with reSET or reSET-O to help communities throughout Wisconsin expand access to addiction care.

Key Points: 
  • Eligible patients will be prescribed and treated with reSET or reSET-O to help communities throughout Wisconsin expand access to addiction care.
  • The state of Wisconsin is making a difference for those struggling with addiction by expanding access to evidence-based treatment and recovery services, said Julia Strandberg, Chief Commercial Officer of Pear Therapeutics.
  • Reduced Healthcare Resource Utilization in Patients with Opioid Use Disorder in the 12 Months After Initiation of a Prescription Digital Therapeutic.
  • Evaluation of real-world outcomes associated with use of a prescription digital therapeutic to treat substance use disorders.

Pear Therapeutics Announces Publication of Real-World Data Showing High Rates of Engagement, Retention and Abstinence with reSET®

Retrieved on: 
Monday, October 24, 2022
Health, General Health, Therapy, Cognitive behavioral therapy, Smartphone, Publication, Treatment, Reading, Williams–Campbell syndrome, Journal, Randomized controlled trial, Safety, Policy, Cannabis, Substance abuse, Population, Policy by press release, Health, Reset, Substance use disorder, MBA, Opioid use disorder, Pear, American Journal, Postgraduate Medicine, Digital, FDA, Current Medical Research and Opinion, Risk, Insomnia, Initiation, Digital therapeutics, Comparison, The American Journal on Addictions, Pharmacoeconomics, Buprenorphine, PDT, Hospital Practice, NIDA, OUD, SUD, Cocaine, PEAR, Efficacy, MD, Doctor of Philosophy, Suicidal ideation, BA, Language isolate, ClinicoEconomics and Outcomes Research, DOI, AJA, Journal of Medical Economics, Pharmaceutical industry, Birth control, Hospital, Mobile phone, Medical device, Health insurance, Nasdaq, Patient

reSET is intended only for patients who own a smartphone and are familiar with use of smartphone apps (applications).

Key Points: 
  • reSET is intended only for patients who own a smartphone and are familiar with use of smartphone apps (applications).
  • Patients should be clearly instructed not to use reSET to communicate to their clinician any urgent or emergent information.
  • Patients with substance use disorder experience mental health disease and co-morbid medical problems at higher rates than the general population.
  • Pear Therapeutics, Inc., which is traded on Nasdaq as PEAR, is the parent company of Pear Therapeutics (US), Inc. Pear is the leader in developing and commercializing software-based medicines, called prescription digital therapeutics (PDTs).

Exact Sciences Expands Leadership in Colorectal Cancer Screening with New Data Presented at the American College of Gastroenterology 2022 Annual Meeting

Retrieved on: 
Monday, October 24, 2022
AGAF, Current Medical Research and Opinion, Risk, American Cancer Society, American College of Gastroenterology, National Comprehensive Cancer Network, The New England Journal of Medicine, Exact sciences, Policy, NASDAQ, United States Preventive Services Task Force, CRC, Traditional serrated adenoma, Annual general meeting, Colorectal cancer, Cancer, Solution, Adenoma, Polyp (medicine), Trial of the century, ACG, Medicare, MD, Blood, Health, American Cancer Society Cancer Action Network, 2021 Essex County Council election, FIT, Methylation, DNA, Inflammatory bowel disease, Death, American College, Manuscript, FDA, Mobile phone, Pharmaceutical industry, Dietary supplement, Health insurance, Colonoscopy, Exact Sciences (company), Facebook, Patient

MADISON, Wis., Oct. 24, 2022 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the company will present new data supporting the positive impact of Cologuard® as a colorectal cancer screening tool during the American College of Gastroenterology (ACG) Annual Meeting, being held October 21-26, 2022. For the first time, data from Exact Sciences will detail the positive impacts on patients when costs associated with follow-up colonoscopy are eliminated after a positive stool-based test. New data will also provide details on the value of Cologuard® in detecting serrated polyps, and the importance of reconsidering the definition of false positive outcomes from stool tests in CRC screening.

Key Points: 
  • "Data from Exact Sciences at ACG demonstrate the positive impact removing obstacles to colorectal cancer screening can have on clinical and economic outcomes associated with this highly preventable form of cancer," said Paul Limburg, MD MPH, AGAF, chief medical officer, Screening, Exact Sciences.
  • The clinical and economic effects of these outcomes were estimated in a cohort of average-risk individuals, newly eligible for colorectal cancer screening.
  • A leading provider of cancer screening and diagnostic tests, Exact Sciences relentlessly pursues smarter solutions providing the clarity to take life-changing action, earlier.
  • For more information, please visit the company's website at www.exactsciences.com , follow Exact Sciences on Twitter @ExactSciences, or find Exact Sciences on Facebook.

US WorldMeds Launches ZIMHIDirect.com

Retrieved on: 
Tuesday, July 5, 2022
FDA, Death, Fever, Current Medical Research and Opinion, Patient, Injection, Blood pressure, Opioid overdose, Caregiver, CEO, Adult, Allergy, Morphine, GLOBE, Nervous, Cardiopulmonary resuscitation, Center, Shivering, Nausea, Law enforcement, Central nervous system, Sneeze, Common, Emergency medical services, History, Irritability, Vomiting, Tramadol, HCL, Perspiration, Yawn, Risk, LLC, Heroin, Weakness, Malignant hyperthermia, Naloxone, EMS, Organization, Dizziness, Centers for Disease Control and Prevention timeline, Seizure, Connecticut Department of Emergency Services and Public Protection, Tremor, Fentanyl, CPR, Diarrhea, Medicine, Emergency, Government, USWM, Restless, Heart rate, Oxycodone, Hydrocodone, CDC, Pharmaceutical industry

It will significantly simplify and streamline the ordering process to ensure our partner organizations can stay focused on their essential roles helping patients facing opioid overdoses, said Breck Jones Sr., CEO of US WorldMeds.

Key Points: 
  • It will significantly simplify and streamline the ordering process to ensure our partner organizations can stay focused on their essential roles helping patients facing opioid overdoses, said Breck Jones Sr., CEO of US WorldMeds.
  • US WorldMeds is a privately held specialty pharmaceutical company that develops, licenses, and markets unique healthcare products designed to improve the lives of patients with challenging conditions and unmet medical needs.
  • US WorldMeds has built a branded product portfolio in the therapeutic areas of opioid withdrawal and malignant hyperthermia.
  • More information on US WorldMeds can be found at www.usworldmeds.com .

Pear Therapeutics Announces New 12-Month Analysis Showing Reduction in Healthcare Resource Utilization and Associated Costs in Patients Treated with reSET-O®

Retrieved on: 
Tuesday, June 14, 2022
Research, General Health, Pharmaceutical, Telemedicine, Virtual Medicine, Mental Health, Health Technology, Clinical Trials, Science, Biotechnology, FDA, Other Science, Health, Opioid use disorder, ClinicoEconomics and Outcomes Research, Adult, BA, Journal, OUD, Doctor of Philosophy, MBA, IP, DOI, Cognitive behavioral therapy, Policy, Pharmacoeconomics, Forward-looking statement, Treatment, Insomnia, Buprenorphine, Therapy, Health, Digital, Language isolate, FDA, Risk, Manuscript, Patient, Current Medical Research and Opinion, Journal of Medical Economics, COVID-19, Suicidal ideation, Safety, PDT, Incidence, Policy by press release, SEC, Postgraduate Medicine, MD, PEAR, Reading, Population, ICU, Medicaid, Terminology, Comparison, Smartphone, Hospital Practice, Pharmaceutical industry, Hospital, Health insurance, Medical device, Nasdaq, Pear

The results of this analysis demonstrated that patients who were treated with reSET-O showed lower incidence of inpatient stays and emergency department visits, compared to control patients.

Key Points: 
  • The results of this analysis demonstrated that patients who were treated with reSET-O showed lower incidence of inpatient stays and emergency department visits, compared to control patients.
  • The study used claims data to evaluate 901 adult patients who were prescribed and treated with reSET-O compared to 978 controls.
  • Reduced healthcare resource utilization in patients with opioid use disorder in the 12 months after initiation of a prescription digital therapeutic.
  • Comparison of Healthcare Resource Utilization Between Patients Who Engaged or Did Not Engage With a Prescription Digital Therapeutic for Opioid Use Disorder.

KemPharm Announces Research Affirming Serdexmethylphenidate’s Lower Potential for Abuse Featured in Peer-Reviewed Publication, Current Medical Research & Opinion

Retrieved on: 
Wednesday, June 1, 2022
Company, Narcolepsy, IND, IH, Hydrocodone, Technology, Benzhydrocodone, Uncertainty, U.S. Securities and Exchange Commission, Food, Share repurchase, Central nervous system, Glycogen storage disease, Ageing, Forward-looking statement, CEO, Current Medical Research and Opinion, DEA, Industry, NDA, CNS, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NPC, AES, Security (finance), Manuscript, Schedule, Patient, Idiopathic hypersomnia, SDX, Private Securities Litigation Reform Act, Facebook, Research, Paracetamol, KMPH, LinkedIn, Corium, ADHD, Gauge (instrument), Attention deficit hyperactivity disorder, Niemann–Pick disease, YouTube, API, FDA, GLOBE, Nasdaq, Twitter, Clinical trial, Compte rendu, Pharmaceutical industry

CELEBRATION, Fla., June 01, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a specialty pharmaceutical company focused on the discovery, development and commercialization of novel treatments for rare central nervous system (CNS), neurodegenerative and lysosomal storage diseases, today announced that a manuscript summarizing the results of three clinical studies involving serdexmethylphenidate (SDX), KemPharm’s prodrug of dexmethylphenidate (d-MPH), was published in the peer-reviewed journal, Current Medical Research & Opinion. The research concluded that SDX has significantly lower potential for abuse and minimal stimulant-like adverse events compared to d-MPH.

Key Points: 
  • The research concluded that SDX has significantly lower potential for abuse and minimal stimulant-like adverse events compared to d-MPH.
  • KemPharm is developing KP1077 as a treatment for idiopathic hypersomnia, a rare neurological sleep disorder, and narcolepsy.
  • We are very pleased that this important research demonstrating SDXs significantly lower abuse potential in comparison to d-MPH was published in the peer-reviewed journal, Current Medical Research & Opinion, stated Travis C. Mickle, Ph.D., President and CEO of KemPharm.
  • This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates.

Comprehensive Study Establishes Cost of Late Detection and Treatment of Cancer

Retrieved on: 
Thursday, May 12, 2022
Cancer, Death, DNA, Current Medical Research and Opinion, Epidemiology, Health, NASDAQ, SEER, Surveillance, Artificial intelligence, United Kingdom, Medicare, Time, MSHS, Technology, GRAIL, Illumina, Inc., Machine learning, LLC, Diagnosis, MD, Medical imaging, Park West Gallery

BEVERLY HILLS, Calif., May 12, 2022 /PRNewswire/ -- Cancer is the second leading cause of death and cancer care costs $1 trillion annually.

Key Points: 
  • An analysis of 2 million Medicare beneficiaries establishes the cost of cancer by stage and time since diagnosis for 17 common cancers.
  • The later the stage at diagnosis, the higher the cost, and this cost difference lasts for at least five years after diagnosis.
  • BEVERLY HILLS, Calif., May 12, 2022 /PRNewswire/ --Cancer is the second leading cause of death and cancer care costs $1 trillion annually.
  • The study establishes a single resource for healthcare professionals, researchers, and payers in addition to providing a starting point to measure the benefit of early cancer detection.

Now Available Over the Counter, LASTACAFT® Provides Eye Allergy Itch Relief in Minutes that Lasts Through 16 Hours

Retrieved on: 
Tuesday, March 15, 2022
YouTube, Twitter, Common, Tree, Acquisition, Neuroscience, ABBV, Food and Drug Administration, Health, News, Failure, Annual report, Private Securities Litigation Reform Act, Itch, Itchy, Allergic conjunctivitis, Risk, AbbVie, COVID-19, Allergy, Central retinal vein occlusion, Safety, Eye, American Academy, Internet, Food, Virology, Pandemic, Research, Instagram, Current Medical Research and Opinion, NYSE, NORTH, Glaucoma, Gastroenterology, Industry, U.S. Securities and Exchange Commission, Diabetic retinopathy, OTC, Epidemic, Retina, LinkedIn, Pollen, Pharmaceutical industry, Cosmetics, Facebook, Allergan

NORTH CHICAGO, Ill., March 15, 2022 /PRNewswire/ -- Allergan, an AbbVie (NYSE: ABBV) company, today announced that LASTACAFT® (alcaftadine ophthalmic solution 0.25%) is now available without a prescription for the estimated 40% of Americans1 who live with ocular allergies. As demonstrated in clinical studies, one drop of LASTACAFT works in as little as three minutes to provide relief from itchy, allergy eyes lasting through 16 hours.2 Following the recent U.S. Food and Drug Administration approval of a complete prescription to over-the-counter (OTC) switch, the original patented prescription-strength formulation of LASTACAFT is now available online and in retail stores where OTC eye drops are sold.

Key Points: 
  • Outdoor allergens, such as pollen from grass, trees, and weeds, and indoor allergens including pet dander, can trigger itchy eyes.
  • LASTACAFT is an antihistamine eye drop that temporarily relieves itchy eyes due to pollen, ragweed, grass, animal hair, and dander for ages two and older.
  • I'm excited that these prescription-strength drops are now accessible without a prescription for those who struggle with itchy, allergy eyes."
  • The safety and efficacy of alcaftadine 0.25% ophthalmic solution for the prevention of itching associated with allergic conjunctivitis.

Medtronic receives FDA approval for InterStim X™ system, the next generation of the most personalized sacral nerve stimulation therapy for bladder and bowel control

Retrieved on: 
Tuesday, February 22, 2022
OAB, United States Census Bureau, Fecal incontinence, Regulation of tobacco by the U.S. Food and Drug Administration, Twitter, Risk, Ministry of Social Affairs, Pain, Prevalence, Smartphone, Security (finance), CD-ROM, United Nations Department of Economic and Social Affairs, Sexual dysfunction, Nation, Research, MRI, WF, Gastroenterology, NYSE, Freedom, U.S. Securities and Exchange Commission, SNM, Food, LinkedIn, Continence, Overactive bladder, Veni, vidi, vici, FDA, Life, Maintenance, RR, Patient, Technology, Chemistry, Current Medical Research and Opinion, Solution, Epidemiology, Society, National Association, FI, Department, Neuroscience, Pharmaceutical industry, Video game console, Electric battery, Medical device, Medical imaging, Medtronic, Urology, Woman, Health

InterStim systems are the standard of care in advanced therapy options, and the most personalized system, to deliver sacral neuromodulation (SNM) therapy.

Key Points: 
  • InterStim systems are the standard of care in advanced therapy options, and the most personalized system, to deliver sacral neuromodulation (SNM) therapy.
  • Both devices are used in the treatment of overactive bladder (OAB), chronic fecal incontinence (FI), and non-obstructive urinary retention.
  • It's exciting to tell patients about the personalized, discreet, smart tech-enabled InterStim choices they now have for long-term relief."
  • "As we celebrate 25 years of InterStim this year, we're bullish about our next chapter in patient-focused therapy innovation."

Pear Therapeutics Announces State of Michigan to Fund Access to Prescription Digital Therapeutics for Substance Use and Opioid Use Disorders

Retrieved on: 
Thursday, February 10, 2022
General Health, Mental Health, Health, Technology, Software, Policy, Hospital Practice, Insomnia, Terminology, Pharmacoeconomics, Cognitive behavioral therapy, PDT, Substance use disorder, Safety, Current Medical Research and Opinion, SEC, Suicidal ideation, Communication, Drug overdose, Journal, ClinicoEconomics and Outcomes Research, DOI, Doctor of Philosophy, Treatment, Therapy, SUD, COVID-19, FDA, Press release, Journal of Medical Economics, Michigan State University, MD, OUD, MBA, Death, Comparison, Buprenorphine, Randomized controlled trial, Risk, Patient, Publication, Smartphone, Reading, Substance abuse, Michigander, BA, Reset, Health, Postgraduate Medicine, Language isolate, PEAR, Opioid use disorder, Population, Opioid overdose, Digital, Pharmaceutical industry, Birth control, Hospital, Medical device, Risk management, Pear, Nasdaq

With todays technology there is a lot more we can do and more people we can help, said Michigan State Representative Joe Bellino.

Key Points: 
  • With todays technology there is a lot more we can do and more people we can help, said Michigan State Representative Joe Bellino.
  • Pear recently released publications showing the potential for improved real-world health outcomes and decreased health care resource utilization for patients using reSET-O5-13.
  • Pear Therapeutics, Inc., which is traded on Nasdaq as PEAR, is the parent company of Pear Therapeutics (US), Inc. Pear is the leader in developing and commercializing software-based medicines, called prescription digital therapeutics (PDTs).
  • Comparison of Healthcare Resource Utilization Between Patients Who Engaged or Did Not Engage With a Prescription Digital Therapeutic for Opioid Use Disorder.